Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marian Hester Harris, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Marian Harris and Andrew Place.
Connection Strength

0.901
  1. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
    View in: PubMed
    Score: 0.189
  2. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90.
    View in: PubMed
    Score: 0.160
  3. Future of clinical genomics in pediatric oncology. J Clin Oncol. 2013 May 20; 31(15):1893-903.
    View in: PubMed
    Score: 0.134
  4. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505.
    View in: PubMed
    Score: 0.059
  5. Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 05 06; 137(18):2463-2480.
    View in: PubMed
    Score: 0.058
  6. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439.
    View in: PubMed
    Score: 0.057
  7. Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885.
    View in: PubMed
    Score: 0.057
  8. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719.
    View in: PubMed
    Score: 0.056
  9. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458.
    View in: PubMed
    Score: 0.048
  10. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
    View in: PubMed
    Score: 0.042
  11. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.